Birth and first-year outcomes in infants of mothers with familial hypercholesterolemia or atherosclerotic cardiovascular disease in the US: A retrospective cohort study
Journal of Clinical Lipidology · 2026-09 · 20 (9) · 1827-1839
DOI: 10.1016/j.jacl.2026.07.032 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Clinical Lipidology, 2026-09. Verfasst von Xinyue Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals Inc, Tarrytown, New York, NY, USA (Liu, Fanous, Ponda, Qiang, Ni, Breskin, Riley, and Knox). Electronic address: xinyue.liu…. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, Atherosclerosis, Mothers. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Regeneron Pharmaceuticals Inc.
Abstract (Originalsprache)
BACKGROUND: Infant outcomes among those born to mothers with familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD) remain unclear. OBJECTIVE: To assess outcomes among infants of mothers living with FH or ASCVD in the US. METHODS: In this retrospective claims-based cohort study, mother-infant singleton pairs (2018-2023) were identified. Infants were followed to death, disenrollment, age 1 year, or the end of 2024. Exposure was classified as maternal prepregnancy diagnosis of FH or ASCVD. Outcomes included preterm birth, low birth weight, macrosomia, neonatal intensive care unit (NICU) admission, major congenital malformations (MCM), infant mortality, and healthcare utilization at 1 year of age. Inverse probability treatment weighting was utilized to compare the FH and ASCVD cohorts with a reference cohort, respectively. RESULTS: Among 275 FH, 878 ASCVD, and 348,683 reference mother-infant pairs, the use of maternal lipid-lowering therapies was rare and declined during pregnancy. No increased risks of adverse outcomes were observed for the FH cohort vs the reference cohort. In contrast, the ASCVD cohort had higher risks of preterm birth (adjusted risk ratio, 1.73 [95% CI, 1.40-2.12]), low birth weight (1.77 [1.28-2.46]), NICU admission (1.48 [1.23-1.77]), and noncardiac MCM (1.58 [1.05-2.37]) than the reference cohort. At 1 year of age, the ASCVD cohort also had higher risks of inpatient admissions, emergency department visits, and urgent care clinic visits. CONCLUSION: Infants of mothers living with ASCVD-but not those with FH-had higher risks of adverse birth outcomes and increased healthcare utilization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Regeneron Pharmaceuticals Inc, Tarrytown, New York, NY, USA (Liu, Fanous, Ponda, Qiang, Ni, Breskin, Riley, and Knox). Electronic address: xinyue.liu@regeneron.com.
- Regeneron Pharmaceuticals Inc, Tarrytown, New York, NY, USA (Liu, Fanous, Ponda, Qiang, Ni, Breskin, Riley, and Knox).
- University of Southern California, Los Angeles, CA, USA (Yang).
Förderung
- Regeneron Pharmaceuticals Inc
Zitieren
APA
Liu, X., Fanous, M., Ponda, M., Qiang, W., Ni, L., Breskin, A., Yang, X., Riley, I. M., & Knox, C. (2026). Birth and first-year outcomes in infants of mothers with familial hypercholesterolemia or atherosclerotic cardiovascular disease in the US: A retrospective cohort study. Journal of Clinical Lipidology, 20(9), 1827-1839. https://doi.org/10.1016/j.jacl.2026.07.032
Vancouver
Liu X, Fanous M, Ponda M, Qiang W, Ni L, Breskin A, et al. Birth and first-year outcomes in infants of mothers with familial hypercholesterolemia or atherosclerotic cardiovascular disease in the US: A retrospective cohort study. Journal of Clinical Lipidology. 2026;20(9):1827-1839. doi:10.1016/j.jacl.2026.07.032
BibTeX
@article{Liu2026,
author = {Liu, Xinyue and Fanous, Michelle and Ponda, Manish and Qiang, Wenqin and Ni, Liang and Breskin, Alexander and Yang, Xiaoran and Riley, Isha M and Knox, Caitlin},
title = {Birth and first-year outcomes in infants of mothers with familial hypercholesterolemia or atherosclerotic cardiovascular disease in the US: A retrospective cohort study},
journal = {Journal of Clinical Lipidology},
year = {2026},
volume = {20},
number = {9},
pages = {1827--1839},
doi = {10.1016/j.jacl.2026.07.032}
}
EUVIMED